Farzad Khademi obtained his M.Sc degree in Medical microbiology from Isfahan University of Medical Sciences, in 2013. During his M.Sc study he worked on the study of mutation in 23SrRNA gene of clarithromycin resistance Helicobacter pylori and resistance pattern to clarithromycin, metronidazole and amoxicillin in patients with gastrointestinal disorders in Isfahan city. In 2017, he obtained his Ph.D, as a medical bacteriologist, from Mashhad University of Medical Sciences, Mashhad, Iran with study on design and construction of a nanovaccine consist of Mycobacterium tuberculosis HspX/EsxS fusion protein encapsulated with MPLA (Monoposphoryl Lipid A) in a new cationic lipid-modified PLGA nanoparticle and evaluation of its immunogenicity after nasal and subcutaneous immunization in mice. He is expert in PCR, gene cloning, recombinant protein expression and purification, western blotting, SDS-PAGE, cell culture, ELISA and cytokine assay.
Epidemiology studies, Drug-resistant of bacteria; Subunit vaccine against M. tuberculosis; Vaccine delivery systems.